Public Consultation: The public consultation was performed from 07/24/2014 to 08/12/2014. After the initial recommendation made by CONITEC of not incorporating arsenic trioxide for APML, the report was submitted to public consultation and has received four contributions, made by a health institution/hospital (1), a medical society (1) and the company that manufactures the technology (2). The contributions brought no new evidence supporting the considerations made by the plenary session members of CONITEC.
Final Deliberation: After analysis of the contributions, the recommendation of not incorporating was kept. The drug has a high cost and was demonstrated to be non-inferior to ATRA, which has a high cure rate. There are options available for the treatment of APML in SUS via APAC procedures. As per treatment guidelines and manuals, arsenic trioxide has been used to treat refractory patients or disease relapse after initial therapy with anthracyclines and ATRA. CONITEC members attending the plenary session meeting on 09/04/2014 unanimously deliberated in favor of not recommending the incorporation of arsenic trioxide as a specific procedure for the treatment of Acute Promyelocytic Leukemia (APML). Deliberation Record nº 97/2014 was signed. 
